Stock ALGS ALIGOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Aligos Therapeutics, Inc. Share Price

Equities

ALGS

US01626L1052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
0.782 USD -4.40% Intraday chart for Aligos Therapeutics, Inc. +4.27% +17.77%
04-03 Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects CI
03-27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 59.17M 4.74B
Net income 2024 * -107M -8.57B Net income 2025 * -116M -9.29B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.94 x
P/E ratio 2025 *
-0.95 x
Employees 66
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.68%
More Fundamentals * Assessed data

Chart Aligos Therapeutics, Inc.

Dynamic Chart

Latest news about Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects CI
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies CI
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) CI
Aligos Therapeutics, Inc. Announces Executive Changes CI
Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023 CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aligos Therapeutics Insider Bought Shares Worth $6,004,149, According to a Recent SEC Filing MT
Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund CI
Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors CI
Aligos Says Investigational New Drug Application Application Cleared By US FDA for Thyroid Hormone Receptor Beta Agonist MT
Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver Congress 2023 CI
More news

Analyst Recommendations on Aligos Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating MT
Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2 MT
Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50 MT
SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating MT
Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11 MT
More recommendations

Press releases Aligos Therapeutics, Inc.

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study AQ
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD AQ
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 GL
More press releases

Quotes and Performance

1 day-4.40%
1 week+4.27%
Current month-20.20%
1 month-23.33%
3 months+13.17%
6 months+22.19%
Current year+17.77%
More quotes

Highs and lows

1 week
0.74
Extreme 0.74
0.90
1 month
0.73
Extreme 0.73
1.10
Current year
0.62
Extreme 0.62
1.20
1 year
0.54
Extreme 0.5388
1.38
3 years
0.54
Extreme 0.5388
34.31
5 years
0.54
Extreme 0.5388
37.51
10 years
0.54
Extreme 0.5388
37.51
More quotes

Managers and Directors - Aligos Therapeutics, Inc.

Managers TitleAgeSince
Lucinda Quan FOU
 Founder 51 04/02/18
Lawrence Blatt CEO
 Chief Executive Officer 62 04/02/18
Lesley Calhoun DFI
 Director of Finance/CFO 58 31/05/20
Members of the board TitleAgeSince
Lawrence Blatt CEO
 Chief Executive Officer 62 04/02/18
Carole Nüchterlein BRD
 Director/Board Member 63 31/07/18
K. Hirth BRD
 Director/Board Member 72 31/07/18
More insiders

ETFs positioned on Aligos Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.00% 2 M€ -.--%
More ETFs positioned on Aligos Therapeutics, Inc.

Quotes

Date Price Change Volume
26/04/24 0.782 -4.40% 110,840
25/04/24 0.818 -1.33% 133,487
24/04/24 0.829 +0.66% 644,254
23/04/24 0.8236 +2.82% 96,855
22/04/24 0.801 +6.80% 470,064

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Sector
Biotechnology & Medical Research
Calendar
07:30am - European Society of Clinical Microbiology and Infectious Diseases Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.782 USD
Average target price
4 USD
Spread / Average Target
+411.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALIGOS THERAPEUTICS, INC. Stock Aligos Therapeutics, Inc.
+17.77% 59.17M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALGS Stock